Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07400952 | Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus | PHASE2 | RECRUITING | 100 | — | — | Dec 23, 2025 | Apr 1, 2027 | Feb 10, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| GLK-221 Ophthalmic Solution | EXPERIMENTAL | GLK-221 Ophthalmic Solution administered topically twice daily to both eyes |
| Placebo | PLACEBO_COMPARATOR | Placebo Ophthalmic Solution administered topically twice daily to both eyes |
| Name | Type | Description |
|---|---|---|
| GLK-221 Ophthalmic Solution | DRUG | GLK-221 Ophthalmic Solution administered twice daily to both eyes |
| Placebo Ophthalmic Solution | DRUG | Placebo Ophthalmic Solution administered twice daily to both eyes |
Inclusion Criteria: * Be ≥ 18 and ≤ 55 years of age * Diagnosis of keratoconus in the study eye Exclusion Criteria: * Pregnant, lactating or planning a pregnancy * Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial